Tier 4 — mechanistic

NAD+ augmentation by nicotinamide riboside engages SLIT2/ROBO1 signaling to attenuate Th17 inflammation in psoriasis

Han K, Klein RJ, Recupero TC, Russo AC, Sharma R, Gupta AK, Hassanzadeh S, Huffstutler RD, Dagur PK, Fisk B, Redekar NR, Sack MN

JCI insight 2026 11; 12; e203826

Bibliography

PubMed: PMID 42048163
PubMed Central: PMC13313537
DOI: 10.1172/jci.insight.203826
Funding: NIH/NHLBI intramural support. ChromaDex supplied NR, placebo and chemical materials without research funding.
Competing interests: The authors reported no financial conflicts and disclosed the material-supply research agreement.

Design	Human clinical and laboratory mechanistic study
Model	Human participants, CD4+ T cells and dermal fibroblasts
Sample	27 volunteers consented; assay-specific analysis sets vary
Intervention	NR 500 mg twice daily versus placebo
Duration	4 weeks
Endpoints	Th17 responsiveness; SLIT2/ROBO1 signaling

The clinical and laboratory study linked NR exposure to reduced Th17 immune responsiveness through SLIT2/ROBO1 signaling.

The clinical and laboratory study linked NR exposure to reduced Th17 immune responsiveness through SLIT2/ROBO1 signaling.

Mechanistic immune outcomes are not equivalent to clinically established psoriasis clearance or proof that NR can replace prescribed treatment.

Editorial review

Last verified 22 October 2026